This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Karl Insogna, MD; John Concato, MD, MS, MPH; Janet Henrich, MD
Yale University School of Medicine New Haven, Conn

JAMA. 1997;277(19):1516-1517.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.

—Dr Atkins interprets the findings of Cauley et al as evidence that HRT for the treatment of osteoporosis will increase the risk of breast cancer. This view differs from that of Cauley et al, who state that HRT "may not increase the risk of breast cancer" in women with osteoporosis who "have had relatively low endogenous estrogen levels" but may, instead, increase the risk for women with "normal or high endogenous estrogen [who] take exogenous estrogen for other indications (eg, to prevent cardiovascular disease)."

The posited relationship between BMD, HRT, and breast cancer risk is complex, as highlighted by the fact that African-American women have higher bone densities and a lower risk of breast cancer than white women,^1-3 indicating that factors other than, or in addition to, estrogen influence both breast cancer risk and bone density. In addition, as we noted in our Editorial, data on past HRT use . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?